Dronedarone

Dronedarone was associated with lower incidence of permanent atrial fibrillation/atrial flutter, more return to permanent sinus rhythm and lower AF/atrial flutter burden vs. placebo, according to a post hoc analysis of the ATHENA trial.

Dronedarone for atrial fibrillation may lower risk for all-cause death and CV hospitalization regardless of HF status or left ventricular ejection fraction, according to research published in the European Journal of Heart Failure.

After atrial fibrillation ablation, dronedarone was associated with lower risk for recurrent hospitalizations and repeat AF ablations compared with sotalol, researchers reported.